Last updated: September 9, 2026
INCB050465, also known as parsaclisib, is an oral, selective phosphatidylinositol 3-kinase delta, or PI3Kδ, inhibitor developed by Incyte for B-cell malignancies. Incyte discontinued the clinical development program after the PI3K inhibitor class faced worsening regulatory, safety and commercial conditions. Parsaclisib has no FDA approval, no marketed product, no Orange Book listing and no established revenue base. Its near-term commercial value is therefore effectively zero unless Incyte or a partner restarts development.
What is INCB050465 and what was it intended to treat?
Parsaclisib was designed to inhibit PI3Kδ, an enzyme involved in B-cell receptor signaling and malignant B-cell survival. The candidate was evaluated primarily in hematologic cancers, including:
- Relapsed or refractory follicular lymphoma
- Marginal zone lymphoma
- Diffuse large B-cell lymphoma
- Chronic lymphocytic leukemia
- Other B-cell non-Hodgkin lymphomas
The program was organized under the CITADEL clinical development program. Incyte pursued parsaclisib as a potentially more selective alternative to earlier PI3K inhibitors, including idelalisib and duvelisib.
PI3Kδ inhibition produced clinical activity in relapsed B-cell malignancies, but the class experienced serious safety issues involving infections, colitis, pneumonitis, hepatotoxicity and treatment-related mortality. These risks reduced the regulatory and commercial value of the entire therapeutic category.
What is the current development status of parsaclisib?
Incyte discontinued development of parsaclisib. The candidate is not an active late-stage commercial program and has not received FDA approval.
| Development attribute |
Status |
| Generic name |
Parsaclisib |
| Development code |
INCB050465 |
| Developer |
Incyte Corporation |
| Mechanism |
Selective PI3Kδ inhibitor |
| Route |
Oral |
| Primary disease focus |
Relapsed or refractory B-cell malignancies |
| Regulatory status |
Not approved |
| FDA application |
No approved NDA identified |
| Orange Book status |
No listing |
| Development status |
Discontinued |
| Commercial status |
Not marketed |
| Current revenue |
None attributable to parsaclisib |
Incyte’s decision followed the broader deterioration of the PI3K inhibitor market. The company’s program had generated response data in lymphoma, but clinical activity did not overcome the class-level concerns around durability, immune-mediated toxicity and the need for complex safety monitoring.
What clinical results did INCB050465 produce?
Parsaclisib generated response signals in several lymphoma studies, particularly in follicular lymphoma and marginal zone lymphoma. The most important development activity occurred in the CITADEL program, which included phase 2 and phase 3 studies.
Reported results showed that parsaclisib could produce tumor responses in heavily pretreated patients. Earlier-stage studies indicated meaningful overall response rates in relapsed follicular lymphoma and marginal zone lymphoma. The commercial question was whether those responses could translate into a favorable benefit-risk profile against established therapies and newer targeted medicines.
The program faced several limitations:
- Responses were measured in diseases with multiple approved and emerging therapies.
- PI3Kδ inhibitors required safety-management protocols that limited treatment duration.
- The class had difficulty demonstrating a durable survival or quality-of-life advantage.
- Regulators became less receptive to broad development strategies for PI3K inhibitors.
- Competing therapies increasingly included BTK inhibitors, EZH2 inhibitors, CAR-T therapy, bispecific antibodies and antibody-drug conjugates.
The clinical data were therefore insufficient to support a sustainable commercial launch.
When did parsaclisib lose exclusivity and commercial momentum?
Parsaclisib did not reach the market, so it did not have a conventional branded-product exclusivity period. Its commercial loss occurred through development discontinuation rather than generic erosion.
A simplified timeline is:
| Period |
Event |
| Mid-to-late 2010s |
Incyte advances parsaclisib into clinical testing for B-cell malignancies |
| 2018-2020 |
CITADEL studies report clinical activity in lymphoma |
| 2020-2021 |
PI3K inhibitor regulatory scrutiny increases following safety concerns involving marketed products |
| 2021-2022 |
Incyte evaluates the strategic and regulatory viability of parsaclisib |
| 2022 |
Parsaclisib development is discontinued |
| 2023-2024 |
No FDA approval, commercial launch or active late-stage program emerges |
The candidate therefore has no practical launch exclusivity, prescription share or revenue protection to defend.
What is the FDA regulatory status of INCB050465?
Parsaclisib is not FDA-approved. No FDA-approved indication, label, dosing regimen or post-marketing safety program exists for the compound.
The FDA’s experience with PI3K inhibitors materially affected the development environment. Idelalisib, duvelisib and umbralisib encountered significant safety and regulatory challenges. Umbralisib was withdrawn from the U.S. market after confirmatory evidence failed to sustain its benefit-risk profile. These events increased the evidentiary burden for subsequent PI3K inhibitor programs.
For parsaclisib, the regulatory barriers included:
- Need for long-term safety follow-up
- Concern over opportunistic infections
- Immune-mediated adverse events
- Potential treatment-related mortality
- Difficulty establishing superior benefit over alternative therapies
- Need for carefully selected patient populations and prophylaxis
No approved label means no FDA-recognized indication for substitution, no reference-listed drug status and no abbreviated new drug application pathway based on parsaclisib.
What is the Orange Book status of parsaclisib?
Parsaclisib has no Orange Book listing because Incyte did not obtain FDA approval for an NDA covering the product.
The absence of an Orange Book record has several consequences:
- No listed U.S. patents tied to an approved product
- No statutory patent certification pathway against an approved reference product
- No conventional Paragraph IV challenge to an approved parsaclisib product
- No Hatch-Waxman litigation record based on an approved parsaclisib NDA
- No regulatory exclusivity attached to a marketed parsaclisib indication
Any future development would likely require a new regulatory strategy rather than a standard generic-entry defense.
Were there Paragraph IV challenges or patent litigation involving INCB050465?
No material Paragraph IV litigation or commercial patent dispute is associated with an approved parsaclisib product because the candidate never reached FDA approval.
Incyte may hold or have held patent rights covering the compound, salts, formulations, dosing regimens, combinations and therapeutic uses. Those rights would not create meaningful market protection without an approved and commercially viable product. The practical value of any remaining patents is limited by:
- The discontinued clinical program
- Lack of an approved reference product
- No established prescriber base
- Class-wide safety concerns
- Competition from newer lymphoma therapies
- The need to generate new clinical data for any revival
The expiration dates and enforceability of individual INCB050465 patent families should not be treated as commercial assets without a confirmed reactivation plan.
What formulations and methods of use were protected?
The development program likely depended on multiple layers of intellectual property rather than a single composition-of-matter right. Relevant categories include:
Compound patents
These cover parsaclisib and potentially related chemical structures, stereoisomers, salts and crystalline forms.
Formulation patents
These may cover oral tablets, excipient systems, dissolution characteristics, stability and manufacturing processes.
Method-of-use patents
Potential claims could cover treatment of follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia or other B-cell malignancies.
Combination patents
Potential combination claims could involve anti-CD20 antibodies, chemotherapy, BTK inhibitors or other targeted agents.
Because there is no approved product, the commercial enforceability of these categories is substantially lower than for the patent estate supporting a marketed oncology drug.
How does parsaclisib compare with competing PI3K inhibitors?
| Drug |
Target |
Status |
Commercial outcome |
| Parsaclisib |
PI3Kδ |
Development discontinued |
No revenue |
| Idelalisib |
PI3Kδ |
Approved in selected hematologic cancers |
Commercially constrained by safety |
| Duvelisib |
PI3Kδ/PI3Kγ |
Approved for selected blood cancers |
Limited uptake and safety pressure |
| Umbralisib |
PI3Kδ/CK1ε |
Approval withdrawn |
Market removed |
| Copanlisib |
PI3Kα/PI3Kδ |
Approved for follicular lymphoma |
Narrower commercial role |
| Inavolisib |
PI3Kα |
Approved in a different oncology setting |
Demonstrates renewed interest in better-defined PI3K development |
Parsaclisib’s selectivity was not enough to differentiate the program commercially. The market shifted toward drugs with clearer biomarker strategies, more manageable safety profiles or stronger outcomes in defined treatment lines.
What is the market projection for INCB050465?
The base-case market projection is zero commercial sales through the medium term because parsaclisib is discontinued and has no approved indication.
| Scenario |
Probability direction |
Commercial outlook |
| Base case: program remains discontinued |
Highest |
No revenue |
| Limited revival in a narrow lymphoma population |
Low |
Small, specialized opportunity |
| Licensing to another oncology company |
Low |
Milestone value possible, but launch probability remains limited |
| Full relaunch across B-cell malignancies |
Very low |
Requires new clinical, regulatory and safety investment |
| Generic competition |
Not relevant currently |
No approved product to copy |
A hypothetical relaunch would face a smaller market than the original development plan assumed. Follicular lymphoma and marginal zone lymphoma remain commercially meaningful indications, but the treatment landscape has changed. Physicians now have access to anti-CD20 regimens, immunomodulatory agents, EZH2 inhibitors, BTK pathway drugs, CAR-T therapies and bispecific antibodies.
A revived parsaclisib program would probably require:
- A narrowly defined patient population
- A differentiated safety protocol
- Prospective infection prophylaxis
- Stronger durability data
- A clear combination strategy
- Evidence against current standards of care
- A regulatory agreement on confirmatory requirements
These requirements would increase development costs while reducing the addressable market.
Which companies are challenging the same market?
Parsaclisib would have competed with companies developing or marketing treatments for relapsed B-cell malignancies, including:
- Gilead Sciences and Kite
- AbbVie and Johnson & Johnson
- Roche and Genentech
- Novartis
- Bristol Myers Squibb
- BeiGene
- AstraZeneca
- MorphoSys and its commercial partners
- Ipsen and other developers of targeted lymphoma therapies
The competitive threat is strongest from products that offer durable responses, outpatient administration or a more defined safety profile. CAR-T products and bispecific antibodies have expanded the treatment options available after multiple prior lines, while targeted oral drugs retain value where tolerability and convenience are favorable.
How strong is the remaining patent and licensing position?
The patent position is commercially weak in the absence of an active program. Incyte remains the principal development rights holder publicly associated with parsaclisib, and no major licensing transaction has established a new commercial owner or active co-development partner.
Potential asset value could exist in:
- Chemical matter
- Selective PI3Kδ inhibition
- Combination use
- Data generated in lymphoma
- Manufacturing know-how
- Safety-management experience
Those assets are unlikely to command a valuation comparable to an active phase 3 oncology program. A buyer would need to discount for clinical restart costs, regulatory risk and competition from approved or late-stage alternatives.
What generic launch risks exist?
There is no immediate generic-launch risk because parsaclisib has no approved product. The relevant risk is development abandonment rather than generic substitution.
If Incyte revived the program and obtained approval, generic risk would depend on:
- Remaining composition-of-matter patent term
- Validity of formulation and method-of-use patents
- Pediatric or other regulatory exclusivity
- Number of approved indications
- Commercial uptake
- Whether the approved product had a clinically meaningful niche
Without an approved reference product, generic manufacturers have no current pathway to launch parsaclisib through the conventional ANDA route.
Key Takeaways
- INCB050465 is parsaclisib, an oral selective PI3Kδ inhibitor developed by Incyte.
- Development was discontinued after clinical, regulatory and commercial problems affecting the PI3K inhibitor class.
- Parsaclisib is not FDA-approved and has no Orange Book listing.
- No material Paragraph IV litigation or generic challenge exists.
- The candidate has no current commercial revenue.
- Any remaining patent rights have limited value without program revival.
- The base-case market forecast is zero sales.
- A relaunch would require new clinical evidence, a narrow target population and a materially improved safety proposition.
FAQs
Is INCB050465 the same drug as parsaclisib?
Yes. INCB050465 is the development code for parsaclisib, an oral selective PI3Kδ inhibitor.
Can patients currently receive parsaclisib commercially?
No. Parsaclisib is not an FDA-approved marketed medicine.
Does parsaclisib have an approved lymphoma indication?
No. The candidate was studied in several B-cell malignancies but did not receive an approved indication.
Is parsaclisib likely to be licensed to another company?
A licensing transaction is possible in principle, but the discontinued status, PI3K class safety history and competitive lymphoma market make a major transaction unlikely without new clinical evidence.
Could parsaclisib return to clinical development?
A return would require substantial additional investment and a new benefit-risk strategy. The most plausible route would be a narrowly selected lymphoma population or a combination regimen supported by new biomarker and safety data.
References
- Incyte Corporation. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Incyte Corporation. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Food and Drug Administration. (2022). FDA approves umbralisib for relapsed or refractory marginal zone lymphoma and follicular lymphoma.
- U.S. Food and Drug Administration. (2022). FDA alerts patients and health care professionals about safety concerns with PI3K inhibitors.
- ClinicalTrials.gov. (n.d.). Studies of parsaclisib in patients with relapsed or refractory B-cell malignancies. U.S. National Library of Medicine.